In Vivo Induction of Membrane Damage by β-amyloid Peptide Oligomers
Overview
Authors
Affiliations
Exposure to the β-amyloid peptide (Aβ) is toxic to neurons and other cell types, but the mechanism(s) involved are still unresolved. Synthetic Aβ oligomers can induce ion-permeable pores in synthetic membranes, but whether this ability to damage membranes plays a role in the ability of Aβ oligomers to induce tau hyperphosphorylation, or other disease-relevant pathological changes, is unclear. To examine the cellular responses to Aβ exposure independent of possible receptor interactions, we have developed an in vivo C. elegans model that allows us to visualize these cellular responses in living animals. We find that feeding C. elegans E. coli expressing human Aβ induces a membrane repair response similar to that induced by exposure to the CRY5B, a known pore-forming toxin produced by B. thuringensis. This repair response does not occur when C. elegans is exposed to an Aβ Gly37Leu variant, which we have previously shown to be incapable of inducing tau phosphorylation in hippocampal neurons. The repair response is also blocked by loss of calpain function, and is altered by loss-of-function mutations in the C. elegans orthologs of BIN1 and PICALM, well-established risk genes for late onset Alzheimer's disease. To investigate the role of membrane repair on tau phosphorylation directly, we exposed hippocampal neurons to streptolysin O (SLO), a pore-forming toxin that induces a well-characterized membrane repair response. We find that SLO induces tau hyperphosphorylation, which is blocked by calpain inhibition. Finally, we use a novel biarsenical dye-tagging approach to show that the Gly37Leu substitution interferes with Aβ multimerization and thus the formation of potentially pore-forming oligomers. We propose that Aβ-induced tau hyperphosphorylation may be a downstream consequence of induction of a membrane repair process.
Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses.
Kadamangudi S, Marcatti M, Zhang W, Fracassi A, Kayed R, Limon A Acta Neuropathol. 2024; 149(1):2.
PMID: 39688618 PMC: 11652575. DOI: 10.1007/s00401-024-02839-2.
Bulgart H, Lopez Perez M, Tucker A, Giarrano G, Banford K, Miller O FASEB J. 2024; 38(20):e70099.
PMID: 39400395 PMC: 11486262. DOI: 10.1096/fj.202401731RR.
Hybrid Amyloid Quantum Dot Nano-Bio Assemblies to Probe Neuroinflammatory Damage.
Chiang W, Urban J, Yanchik-Slade F, Stout A, Hammond J, Nilsson B ACS Chem Neurosci. 2024; 15(17):3124-3135.
PMID: 39146244 PMC: 11378299. DOI: 10.1021/acschemneuro.4c00183.
Leveraging Plasma Membrane Repair Therapeutics for Treating Neurodegenerative Diseases.
Bulgart H, Goncalves I, Weisleder N Cells. 2023; 12(12).
PMID: 37371130 PMC: 10297337. DOI: 10.3390/cells12121660.
Lipid rafts and human diseases: why we need to target gangliosides.
Fantini J FEBS Open Bio. 2023; 13(9):1636-1650.
PMID: 37052878 PMC: 10476576. DOI: 10.1002/2211-5463.13612.